GR3034535T3 - Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer - Google Patents

Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer

Info

Publication number
GR3034535T3
GR3034535T3 GR20000402225T GR20000402225T GR3034535T3 GR 3034535 T3 GR3034535 T3 GR 3034535T3 GR 20000402225 T GR20000402225 T GR 20000402225T GR 20000402225 T GR20000402225 T GR 20000402225T GR 3034535 T3 GR3034535 T3 GR 3034535T3
Authority
GR
Greece
Prior art keywords
antisense oligonucleotides
cancer
treatment
protein kinase
regulatory subunit
Prior art date
Application number
GR20000402225T
Other languages
English (en)
Inventor
Yoon S Cho-Chung
Original Assignee
Yoon S Cho Chung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoon S Cho Chung filed Critical Yoon S Cho Chung
Publication of GR3034535T3 publication Critical patent/GR3034535T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR20000402225T 1990-11-02 2000-10-02 Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer GR3034535T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60711390A 1990-11-02 1990-11-02
US68019891A 1991-04-05 1991-04-05
US07/702,163 US5271941A (en) 1990-11-02 1991-05-20 Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
EP91118628A EP0490077B1 (en) 1990-11-02 1991-10-31 Antisense oligonucleotides for treatment of cancer

Publications (1)

Publication Number Publication Date
GR3034535T3 true GR3034535T3 (en) 2001-01-31

Family

ID=27416969

Family Applications (2)

Application Number Title Priority Date Filing Date
GR970402319T GR3024673T3 (en) 1990-11-02 1997-09-10 Antisense oligonucleotides for treatment of cancer
GR20000402225T GR3034535T3 (en) 1990-11-02 2000-10-02 Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR970402319T GR3024673T3 (en) 1990-11-02 1997-09-10 Antisense oligonucleotides for treatment of cancer

Country Status (9)

Country Link
US (3) US5271941A (el)
EP (3) EP0785252B1 (el)
KR (1) KR0171210B1 (el)
AT (2) ATE156517T1 (el)
CA (2) CA2488792A1 (el)
DE (2) DE69132299T2 (el)
DK (2) DK0785252T3 (el)
ES (2) ES2148838T3 (el)
GR (2) GR3024673T3 (el)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5646267A (en) * 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US5359052A (en) * 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US6995146B2 (en) * 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
EP0750516A4 (en) 1993-03-26 1998-07-01 Univ Jefferson METHOD FOR INHIBITING CELL PROLIFERATION AND TRIGGERING CELL DIFFERENTIATION USING TYPE 1 GROWTH FACTOR RECEPTOR OLIGONUCLEOTIDES
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5639872A (en) * 1993-07-27 1997-06-17 Hybridon, Inc. Human VEGF-specific oligonucleotides
ATE286125T1 (de) * 1993-09-20 2005-01-15 Univ Pennsylvania Regulation der genexpression von bcl-2
US5618709A (en) * 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US6608035B1 (en) * 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US7074768B2 (en) * 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US6624293B1 (en) * 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US20050054600A1 (en) * 1995-08-17 2005-03-10 Hybridon, Inc. Modified protein kinase a-specific oligonucleotides and methods of their use
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
WO1998040479A1 (en) * 1997-03-12 1998-09-17 Hybridon, Inc. Modified protein kinase a-specific oligonucleotides and methods of their use
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6312941B1 (en) 1997-11-26 2001-11-06 The Regents Of The University Of Michigan Compositions and methods for identifying signaling pathway agonists and antagonists
AU5618700A (en) * 1999-06-18 2001-01-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6489356B2 (en) 2000-09-05 2002-12-03 Edward Leung Method for treating pain in humans
WO2002026932A2 (en) 2000-09-26 2002-04-04 Duke University Rna aptamers and methods for identifying the same
AU2001296846B2 (en) 2000-10-12 2007-07-05 University Of Rochester Compositions that inhibit proliferation of cancer cells
KR100408916B1 (ko) * 2000-11-23 2003-12-11 주식회사 바이오제니아 마이코락톤을 함유하는 항암제, 사람 레티노블라스토마단백질의 발현을 저하시키는 안티센스 올리고누클레오티드및 마이코락톤과 상기 안티센스 올리고누클레오티드를함유하는 항암제
US6524854B1 (en) * 2001-09-11 2003-02-25 Isis Pharmaceuticals, Inc. Antisense inhibition of PKA regulatory subunit RII alpha expression
EP2363405A1 (en) 2002-02-06 2011-09-07 Stasys Technologies, Inc. Anti-infarction molecules
AU2003253580A1 (en) * 2002-02-26 2003-11-17 University Of Minnesota Variants of nedd4l associated with hypertension and viral budding
EP1575992A4 (en) 2002-08-05 2007-02-21 Univ Rochester CHIMERIC PROTEINS WITH PROTEIN TRANSDUCTION FIELD / DOMAINE DESAMINASE, ASSOCIATED COMPOUNDS AND CORRESPONDING USES
AU2003293412A1 (en) * 2002-12-05 2004-06-30 The Research Foundation Of State University Of Newyork HIGH EFFICACY ANTISENSE RiAlpha PKA POLY-DNP OLIGORIBONUCLEOTIDES
US20050069918A1 (en) 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
AU2005247319B2 (en) * 2004-04-28 2011-12-01 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
US20080276327A1 (en) 2004-05-21 2008-11-06 University Of Utah Research Foundation Methods and Compositions Related to Delivery of Chemical Compounds to Invertebrate Embryos
WO2007001324A2 (en) 2004-07-23 2007-01-04 The University Of North Carolina At Chapel Hill Methods and materials for determining pain sensitivity and predicting and treating related disorders
RS59399B1 (sr) 2005-03-23 2019-11-29 Genmab As Antitela protiv cd38 za lečenje multiplog mijeloma
WO2007011702A2 (en) * 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2189522A1 (en) 2005-10-14 2010-05-26 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
EP2066812A4 (en) 2006-09-21 2010-04-28 Univ Rochester COMPOSITIONS AND METHODS RELATING TO SLIDER THERAPY OF PROTEINS FOR MYOTONIC DISTROPHY
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
EP2104509A4 (en) 2006-12-11 2010-03-24 Univ Utah Res Found COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGICAL ANGIOGENESIS AND VASCULAR PERMEABILITY
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
EP2288922B1 (en) 2008-05-08 2016-08-17 University of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
CA2734322A1 (en) * 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
EP3071590A4 (en) 2013-11-21 2017-07-19 SeNA Research, Inc. Methods for structural determination of selenium derivatized nucleic acid complexes
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
TW201641691A (zh) * 2015-02-04 2016-12-01 必治妥美雅史谷比公司 Ｔａｕ反義寡聚物及其用途
US11761951B2 (en) 2015-02-04 2023-09-19 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
CA3032124A1 (en) 2016-07-28 2018-02-01 Regeneron Pharmaceuticals, Inc. Gpr156 variants and uses thereof
EP3496736A4 (en) 2016-08-03 2020-05-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. THERAPEUTICS AGAINST TLR9
CN110199032A (zh) 2017-01-23 2019-09-03 雷杰纳荣制药公司 羟基类固醇17-β脱氢酶13(HSD17B13)变体及其用途
JP2020527329A (ja) 2017-06-05 2020-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｂ４ｇａｌｔ１バリアント及びその使用
EP3679158A1 (en) 2017-09-06 2020-07-15 Regeneron Pharmaceuticals, Inc. Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
SG11202001792UA (en) 2017-09-07 2020-03-30 Regeneron Pharma Solute carrier family 14 member 1 (slc14a1) variants and uses thereof
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
RU2020115869A (ru) 2017-10-16 2021-11-19 Ридженерон Фармасьютикалз, Инк. Варианты корнулина (crnn) и их применение
WO2021003295A1 (en) 2019-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Modulators of hsd17b13 and methods of use thereof
WO2024173343A1 (en) 2023-02-14 2024-08-22 Regeneron Pharmaceuticals, Inc. Compounds targeting hydroxysteroid 17-beta dehydrogenase (hsd17b) and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
NO864301L (no) * 1986-10-28 1988-04-29 Tore Jahnsen Dna-prober for human regulatorisk enhet av camp-avhengige proteinkinaser.
WO1990000624A1 (en) * 1988-07-05 1990-01-25 Baylor College Of Medecine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases

Also Published As

Publication number Publication date
CA2054325A1 (en) 1992-05-03
CA2488792A1 (en) 1992-05-03
CA2054325C (en) 2005-03-15
DE69132299D1 (de) 2000-08-10
KR0171210B1 (ko) 1999-02-01
ES2148838T3 (es) 2000-10-16
ATE156517T1 (de) 1997-08-15
US5271941A (en) 1993-12-21
ATE194383T1 (de) 2000-07-15
US5691317A (en) 1997-11-25
DE69127175T2 (de) 1998-03-12
EP0490077A1 (en) 1992-06-17
DK0785252T3 (da) 2000-10-02
DE69127175D1 (de) 1997-09-11
US5627158A (en) 1997-05-06
EP0490077B1 (en) 1997-08-06
EP0972831A1 (en) 2000-01-19
EP0785252A1 (en) 1997-07-23
DK0490077T3 (da) 1998-01-26
GR3024673T3 (en) 1997-12-31
EP0785252B1 (en) 2000-07-05
ES2104644T3 (es) 1997-10-16
DE69132299T2 (de) 2001-02-15

Similar Documents

Publication Publication Date Title
GR3034535T3 (en) Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer
SE9301951D0 (sv) Methods for administration of taxol
IL222002B (en) A preparation of taxane for the treatment of cancer, restenosis and retinopathy
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
IL133784A (en) Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
IL125776A (en) Use of a cimicifuga racemosa extract for the manufacture of a drug for treating estrogen-dependent tumors
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
PL322732A1 (en) Pharmaceutic agent containing n-chlorophenyl carbaminates and n-chlorophenyl thiocarbaminates for inhibiting development of viruses and carcinoma
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
PT1076561E (pt) Terapia de combinacao para o tratamento de tumores
HUP9802536A3 (en) Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence
DK0465512T3 (da) Regional kemoterapi med 4-hydroperoxycyclophosphamid

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees